Observational Non-Interventional Study Of Febrile Neutropenia Patients To Evaluate Antibacterial Therapeutical Options

Pfizer

Status: Completed

Conditions: Febrile Neutropenia

Treatments: Drug: Antibacterial agent for the treatment of febrile neutropenia

Study type: Observational

Funder types: Industry

Identifiers

NCT00945555

A1891006

Details and patient eligibility

About

The purpose of this study was to define and classify antibacterial agents used in Turkey for patients with febrile neutropenia.

Enrollment: 264 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who are 18 years old and above.
• Patients who have undergone allogeneic/autologous or peripheral stem cell transplantation following induction or consolidation treatment due to acute hematological malignancy.
• Patients who have a neutrophil count below 500 cells per cubic millimeter (cells/mm^3) or below 1000 cells/mm^3 with an expectancy to rapidly decrease below 500 cells/mm^3.
• Patients with a body temperature more than or equal to (≥)38.3 degrees Celsius (101 degrees Fahrenheit) on single oral measurement or detected ≥38.0 degrees Celsius for at least an hour and thus started on antibacterial treatment will be included in the trial.

Exclusion criteria

• Patients who are pregnant or considering pregnancy.

Trial design

264 participants in 1 patient group

All participants

Description:

Participants with febrile neutropenia who received antibacterial treatment per investigator's judgment

Treatment:

Drug: Antibacterial agent for the treatment of febrile neutropenia